The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

As the hostilities in the wider Middle East escalate, 7 October 2024 marks one-year since the Hamas-Israel conflict began. Israel's response escalated into conflicts with other organisations, ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Advarra, the market leader in regulatory review solutions and clinical research technology for sites, sponsors, and clinical ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.

However other BTK inhibitors such as AbbVie/Janssen’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence are already approved in several different types of blood cancer, making this a possible ...

CNN anchor Jim Acosta cut short an interview with Corey Lewandowski after he repeatedly mispronounced Vice President Kamala Harris’ name despite being corrected. The discussion grew heated over ...

Sep. 10, 2024 — Phase separation, when molecules part like oil and water, works alongside oxygen diffusion to help memristors -- electrical components that store ... Electrically Modulated Light ...

Pythons to highly venomous king browns, the course offered in the Northern Territory at TAFE seeks to prepare students for every kind of slithery encounter. A letter seen by the ABC shows the ...